Guggenheim analyst Brad Canino initiated coverage of Kura Oncology (KURA) with a Neutral rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Optimistic Buy Rating for Kura Oncology: KO-2806’s Potential in ccRCC and Market Opportunities
- Kura Oncology’s KO-2806: A Promising Investment with $1.5 Billion Market Potential in RCC
- Kura Oncology’s Earnings Call: Progress Amidst Challenges
- Kura Oncology price target lowered to $24 from $28 at Citizens JMP
- Kura Oncology price target lowered to $27 from $29 at BofA